Prime Highlights
- Dual listings are helping healthcare firms access global capital and expand overseas.
- Companies are investing heavily in AI, robotics and digital healthcare.
Key Facts
- Edge Medical’s market share reached 30%.
- Aier’s overseas revenue hit RMB3.1 billion in 2025.
Background
A growing number of Chinese healthcare companies are pursuing dual primary listings in Mainland China and Hong Kong as part of a broader strategy to expand globally, attract international investors and strengthen overseas operations, according to a report by UOB.
The report said Hong Kong is increasingly becoming a preferred platform for healthcare firms seeking access to global capital markets, international talent and cross-border growth opportunities. The trend reflects the maturity of China’s domestic healthcare market and the sector’s ambition to build a stronger global presence.
In addition, Chinese healthcare companies are moving outside of healthcare services to invest in advanced technologies. Areas of focus here include the application of artificial intelligence to diagnostics, robotic surgery, intelligent hospital solutions, drug discovery, and digital health platforms that connect patients, doctors, and insurance companies.
Another one of the companies that will benefit from high foreign interest will be Edge Medical. The firm expects a better than expected performance for 2026 with the acceptance of their robotic surgeons abroad. Foreign installations of their devices now exceed 100 units, and their market share in China has risen to about 30%, thereby reducing the distance between itself and the leader of the industry. It has received approval in Europe and China for its new robot-based solution, and plans to share buybacks to boost its EPS.
On the other hand, Aier Eye Hospital Group is pursuing rapid growth overseas through acquisition in Brazil, thus developing an eye-care network with 81 centres. This helps in further strengthening its position in Latin America and in achieving its aim for listing overseas. Revenue from overseas operations increased by 16.5% in 2025 and accounted for close to 14% of total revenue.
The tech company ByteDance is further expanding its footprint in healthcare through substantial investment in an AI-based hospital complex in Beijing, and by exploring AI-based drug discovery initiatives against autoimmune diseases.
